z i m m e r h o l d i n g s , i n c .
a n d s u b s i d i a r i e s 2 0 0 4 f o r m 1 0 - k notes to consolidated financial statements ( continued ) the company and implex had been operating since 2000 , the following table summarizes the estimated fair values relating to the development and distribution of reconstructive of the assets acquired and liabilities assumed at the date of implant and trauma products incorporating trabecular metal the implex acquisition : ( in millions ) technology .
as ofthe merger agreement contains provisions for additional april 23 , 2004annual cash earn-out payments that are based on year-over- current assets $ 23.1year sales growth through 2006 of certain products that .

as of april 23 2004
current assets
$ 23.1
property plant and equipment
4.5
intangible assets subject to amortization:
core technology ( 30 year useful life )
3.6
developed technology ( 30 year useful life )
103.9
other assets
14.4
goodwill
61.0
total assets acquired
210.5
current liabilities
14.1
deferred taxes
43.3
total liabilities assumed
57.4
net assets acquired
$ 153.1

estimates total earn-out payments , including payments core technology ( 30 year useful life ) 3.6 already made , to be in a range from $ 120 to $ 160 million .
developed technology ( 30 year useful life ) 103.9 other assets 14.4these earn-out payments represent contingent consideration goodwill 61.0and , in accordance with sfas no .
141 and eitf 95-8 2018 2018accounting for contingent consideration paid to the total assets acquired 210.5 shareholders of an acquired enterprise in a purchase current liabilities 14.1 deferred taxes 43.3business combination 2019 2019 , are recorded as an additional cost of the transaction upon resolution of the contingency and total liabilities assumed 57.4 therefore increase goodwill .
net assets acquired $ 153.1the implex acquisition was accounted for under the purchase method of accounting pursuant to sfas no .
141 .
4 .
change in accounting principle accordingly , implex results of operations have been included in the company 2019s consolidated results of operations instruments are hand held devices used by orthopaedic subsequent to april 23 , 2004 , and its respective assets and surgeons during total joint replacement and other surgical liabilities have been recorded at their estimated fair values in procedures .
effective january 1 , 2003 , instruments are the company 2019s consolidated statement of financial position as recognized as long-lived assets and are included in property , of april 23 , 2004 , with the excess purchase price being plant and equipment .
undeployed instruments are carried at allocated to goodwill .
pro forma financial information has not cost , net of allowances for obsolescence .
instruments in the been included as the acquisition did not have a material field are carried at cost less accumulated depreciation .
impact upon the company 2019s financial position , results of depreciation is computed using the straight-line method operations or cash flows .
based on average estimated useful lives , determined the company completed the preliminary purchase price principally in reference to associated product life cycles , allocation in accordance with u.s .
generally accepted primarily five years .
in accordance with sfas no .
144 , the accounting principles .
the process included interviews with company reviews instruments for impairment whenever management , review of the economic and competitive events or changes in circumstances indicate that the carrying environment and examination of assets including historical value of an asset may not be recoverable .
an impairment loss performance and future prospects .
the preliminary purchase would be recognized when estimated future cash flows price allocation was based on information currently available relating to the asset are less than its carrying amount .
to the company , and expectations and assumptions deemed depreciation of instruments is recognized as selling , general reasonable by the company 2019s management .
no assurance can and administrative expense , consistent with the classification be given , however , that the underlying assumptions used to of instrument cost in periods prior to january 1 , 2003 .
estimate expected technology based product revenues , prior to january 1 , 2003 , undeployed instruments were development costs or profitability , or the events associated carried as a prepaid expense at cost , net of allowances for with such technology , will occur as projected .
the final obsolescence ( $ 54.8 million , net , at december 31 , 2002 ) , and purchase price allocation may vary from the preliminary recognized in selling , general and administrative expense in purchase price allocation .
the final valuation and associated the year in which the instruments were placed into service .
purchase price allocation is expected to be completed as the new method of accounting for instruments was adopted soon as possible , but no later than one year from the date of to recognize the cost of these important assets of the acquisition .
to the extent that the estimates need to be company 2019s business within the consolidated balance sheet adjusted , the company will do so .
and meaningfully allocate the cost of these assets over the periods benefited , typically five years .
the effect of the change during the year ended december 31 , 2003 was to increase earnings before cumulative effect of change in accounting principle by $ 26.8 million ( $ 17.8 million net of tax ) , or $ 0.08 per diluted share .
the cumulative effect adjustment of $ 55.1 million ( net of income taxes of $ 34.0 million ) to retroactively apply the .

Question: what is the percent difference in total assets acquired and net assets acquired?
Answer: 37.5%